---
title: Reduce off time with infusion
nct_id: NCT07382440
status: RECRUITING
sponsor: AbbVie
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07382440"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07382440"
last_fetched: "2026-05-10T14:05:14.416Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce off time with infusion

**Goal (in five words):** Reduce off time with infusion

**Official Title:** Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa/Foscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.

**Trial ID:** [NCT07382440](https://clinicaltrials.gov/study/NCT07382440)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** AbbVie
- **Target Enrollment:** 120 participants
- **Start Date:** 2026-03-09
- **Completion Date:** 2028-09
- **Conditions:** Parkinson's Disease

## Summary For Families

The goal is to see whether giving foslevodopa/foscarbidopa as a continuous subcutaneous infusion can reduce motor fluctuations and "off" time for people with advanced Parkinson's in routine Belgian care. Foslevodopa and foscarbidopa are prodrugs that convert to levodopa and carbidopa after infusion, allowing a steady, under-the-skin delivery of levodopa instead of uneven oral doses, which can smooth plasma levels and often reduce wearing-off; it replaces or supplements oral levodopa under clinician supervision. The study is looking for adults 18 and older with advanced Parkinson's who were evaluated in hospital and already planned to start the commercially available subcutaneous treatment, excluding anyone in another interventional trial or being evaluated for the treatment outside a hospital.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent.
* Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study.

Exclusion Criteria:

* Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp.
* Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.
```

## Locations (10)

- Universitair Ziekenhuis Antwerpen /ID# 279434, Edegem, Antwerpen, Belgium _(51.1566, 4.4450)_
- Chu Tivoli /ID# 279455, La Louvière, Hainaut, Belgium _(50.4866, 4.1879)_
- Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452, Tournai, Hainaut, Belgium _(50.6071, 3.3893)_
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454, Hasselt, Limburg, Belgium _(50.9311, 5.3378)_
- UZ Gent /ID# 279433, Ghent, Oost-Vlaanderen, Belgium _(51.0500, 3.7167)_
- Universitair Ziekenhuis Leuven /ID# 279439, Leuven, Vlaams-Brabant, Belgium _(50.8796, 4.7009)_
- AZ Sint-Jan Brugge /ID# 279422, Bruges, West-Vlaanderen, Belgium _(51.2089, 3.2242)_
- Az Groeninge Campus Kennedylaan /ID# 279423, Kortrijk, West-Vlaanderen, Belgium _(50.8280, 3.2649)_
- AZ Oostende /ID# 279461, Ostend, West-Vlaanderen, Belgium _(51.2155, 2.9270)_
- AZ-Delta. /ID# 279437, Roeselare, West-Vlaanderen, Belgium _(50.9465, 3.1227)_

## Central Contacts

- Clementine Semanaz — (CONTACT) — 844-663-3742 — clementine.semanaz@abbvie.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07382440*  
*HTML version: https://parkinsonspathways.com/trial/NCT07382440*  
*Source data: https://clinicaltrials.gov/study/NCT07382440*